PBIO — Pressure BioSciences Income Statement
0.000.00%
Last trade - 00:00- $0.13m
- $28.74m
- $1.98m
Annual income statement for Pressure BioSciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.81 | 1.22 | 2 | 1.73 | 1.98 |
| Cost of Revenue | |||||
| Gross Profit | 0.613 | 0.638 | 1.06 | -0.285 | 0.8 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 8.41 | 9.38 | 7.25 | 7.38 | 15.5 |
| Operating Profit | -6.6 | -8.16 | -5.25 | -5.65 | -13.5 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -11.9 | -16 | -20.2 | -16.1 | -29.3 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -11.7 | -16 | -20.2 | -16.1 | -29.3 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -11.7 | -16 | -20.2 | -16.1 | -29.3 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -15.9 | -17.6 | -22.7 | -17.8 | -35.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -7.72 | -4.24 | -3.26 | -1.54 | -1.33 |